Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LAM-001 for Bronchiolitis Obliterans Syndrome (INSPO-BOS)
NCT06018766Phase 2Recruiting
- Start
- Aug 2023
- Primary completion
- Dec 2026
- Modality
- Inhalation Devices, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of LAM-001 in Bronchiolitis Obliterans Syndrome (BOS). Started Aug 2023; status: recruiting.
02
Drugs
LAM-001
03
Conditions
Bronchiolitis Obliterans Syndrome (BOS)
Beyond the preview
Go deeper on NCT06018766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06018766.